Select your localized edition:

Close ×

More Ways to Connect

Discover one of our 28 local entrepreneurial communities »

Be the first to know as we launch in new countries and markets around the globe.

Interested in bringing MIT Technology Review to your local market?

MIT Technology ReviewMIT Technology Review - logo


Unsupported browser: Your browser does not meet modern web standards. See how it scores »

{ action.text }

Let’s take a moment to consider what the University of Rochester researchers accomplished. The story begins back in the 1960s, when Rochester biochemist Donald Young studied an enzyme called cyclooxygenase, or “cox,” whose activity is blocked by aspirin and other anti-inflammatory drugs. Young’s research led him to distinguish between two distinct parts of the enzyme that he came to dub cox-1 and cox-2.

Further study of cox-1 showed that it does not even play a role in inflammation itself but rather, among other things, regulates the secretion of gastric acid in the stomach. In the distinction between the functions of cox-1 and cox-2, the team recognized a potential gold mine: they might be able to directly target cox-2, thereby suppressing pain and inflammation without causing stomach irritation, the bane of all previous painkillers-from aspirin to ibuprofen-that act on the cox enzyme.

Simply discovering cox-2 was an important contribution to the field. But the researchers didn’t stop there. By the early 1990s, Young’s team identified the gene in humans that is responsible for producing cox-2 and discovered how it causes inflammation within individual cells. The group even developed a method for testing to see whether given compounds might selectively inhibit cox-2 in humans.

No matter how you look at it, in other words, there is little question that the pioneering University of Rochester work paved the way for a new generation of painkillers that would be easy on the stomach. And in 2000-after eight years-the U.S. Patent Office granted the Rochester team a broad patent covering a “method” for selectively inhibiting cox-2.

What’s really at issue in this case is whether our patent system can reasonably be made to account for seminal research contributions like the one made by Young and his team. It is not a simple question. Sure, the university researchers didn’t do the costly drug development or the clinical testing required to bring Celebrex and Vioxx to market. And narrow and specific patent claims tend rightly to reward those who assume precisely those kinds of laborious and costly roles.

But universities are not in the drug development business. In this case, there seems to be little doubt that Celebrex and Vioxx are on the market today only because of the pathbreaking contribution made by the Rochester researchers. The university has already announced that it will appeal the decision; this will be a critical intellectual-property case to watch. Judge Larimer opined that a broad and nonspecific patent claim is little more than “an attempt to preempt the future before it has arrived.” I’m so strongly in agreement with that sentiment that it is echoed in the very name of this column. But we need a patent system that distinguishes between those who would “preempt” the future and those who actually help create it.

0 comments about this story. Start the discussion »

Tagged: Business

Reprints and Permissions | Send feedback to the editor

From the Archives


Introducing MIT Technology Review Insider.

Already a Magazine subscriber?

You're automatically an Insider. It's easy to activate or upgrade your account.

Activate Your Account

Become an Insider

It's the new way to subscribe. Get even more of the tech news, research, and discoveries you crave.

Sign Up

Learn More

Find out why MIT Technology Review Insider is for you and explore your options.

Show Me